- Home
- FENC
as 07-25-2025 4:00pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 222.9M | IPO Year: | 2001 |
| Target Price: | $13.00 | AVG Volume (30 days): | 68.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $9.30 | Next Earning Date: | 08-12-2025 |
| Revenue: | $30,912,000 | Revenue Growth: | -31.23% |
| Revenue Growth (this year): | 0.85% | Revenue Growth (next year): | 55.16% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Raykov Rosty | FENC | Director | Jun 5 '25 | Sell | $7.78 | 10,000 | $77,800.00 | 65,462 | |
| Hackman Jeffrey S. | FENC | Chief Executive Officer | May 16 '25 | Buy | $6.87 | 15,000 | $104,601.60 | 1,035 | |
| Raykov Rosty | FENC | Director | May 16 '25 | Sell | $6.78 | 16,667 | $113,002.26 | 65,462 | |
| Raykov Rosty | FENC | Director | May 5 '25 | Sell | $6.31 | 10,000 | $63,100.00 | 65,462 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why
GlobeNewswire
2 months ago
Fennec Announces Results of Annual Meeting
Simply Wall St.
2 months ago
Fennec Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations
GuruFocus.com
2 months ago
Fennec Pharmaceuticals Inc (FENC) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amid ...
Thomson Reuters StreetEvents
2 months ago
Q1 2025 Fennec Pharmaceuticals Inc Earnings Call
MT Newswires
2 months ago
Fennec Swings to Q1 Loss on Lower Revenue, but Pedmark Sales up; Shares 10% Higher in U.S. Pre-market
GlobeNewswire
2 months ago
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.